CRISPR Therapeutics (CRSP) Financial Analysis & Valuation | Quarter Chart
CRISPR Therapeutics (CRSP)
CRSPPrice: $56.35
Fair Value: 🔒
🔒score
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allo... more
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serio... more
Description
Shares
| Market Cap | $5.43B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | CH | CEO | Samarth Kulkarni |
| IPO Date | 2016-10-19 | CAGR | — |
| Employees | 393 | Website | www.crisprtx.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
CRSP chart loading...
Fundamentals
Technicals
| Enterprise Value | $5.47B | P/E Ratio | -11.03 |
| Forward P/E | -14.71 | PEG Ratio | — |
| P/S Ratio | 1471.03 | P/B Ratio | 3.32 |
| P/CF Ratio | -15.04 | P/FCF Ratio | -15.05 |
| EPS | $-5.11 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | -88.91% | Gross Margin | -53.61% |
| Operating Margin | -134.08% | Profit Margin | -138.57% |
| ROE | -0.31% | ROA | -0.21% |
| ROCE | -0.21% | Current Ratio | 17.96 |
| Quick Ratio | 17.96 | Cash Ratio | 3.11 |
| Debt/Equity | 0.43 | Interest Coverage | — |
| Altman Z Score | 2.88 | Piotroski Score | 3 |